HighGravityDataFMC Corporation — Feb 4, 2026 release
Fiscal 2025 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000037785-26-000036
Showing in the filing
Debt paydown
“$1 billion”
Period
FY2026
Measure
Company-defined measure
Source
Prose
All guidance in this release · 17
Debt paydown for FY2026
“$1 billion”
Debt reduction for FY2026
“$1 billion”
Revenue for FY2026
“$3.60 billion to $3.80 billion”
Sales of new active ingredients for FY2026
“between $300 million and $400 million”
Additional tariff charges for FY2026
“approximately $20 million”
Free cash flow for FY2026
“negative $65 million to $65 million dollars”
Revenue for Q1 FY2026
“between $725 million and $775 million”
Adjusted EBITDA for Q1 FY2026
“between $45 million and $55 million”
Adjusted EPS for Q1 FY2026
“negative $0.44 to negative $0.32”
Revenue excluding India for FY2026
“$3.60 billion to $3.80 billion”
Revenue excluding India for Q1 FY2026
“$725 million to $775million”
Growth at midpoint vs. 2025 (Revenue) for Q1 FY2026
“-5%”
Adjusted EBITDA for FY2026
“$670 million to $730 million”
Adjusted EPS for FY2026
“$1.63 to $1.89”
Growth at midpoint vs. 2025 (Adjusted EPS) for FY2026
“$(1.20)”
Growth at midpoint vs. 2025 (Adjusted EPS) for Q1 FY2026
“$(0.56)”
Adjusted EPS diluted shares assumption
“125.7 million diluted shares for full year and 125.7 million diluted shares for Q1”
Exhibit 99.1 · the passage around this item
… earlier in the release
The company also reported fourth quarter and full year 2025 results and provided its 2026 outlook. FMC is focused on executing its 2026 operational priorities, one of which is strengthening the balance sheet by paying down $1 billion in debt through asset sales and licensing agreements. This includes the previously announced sale of the India commercial business. Further priorities focus on improving the competitiveness of the company's legacy core portfolio and managing the post-patent transition for Rynaxypyr® active. FMC will also continue advancing commercialization of new active ingredients, including Isoflex® active, fluindapyr, Dodhylex® active and rimisoxafen. In addition, the company will explore strategic options. FMC's four new active ingredients, along with its broader development pipeline, are unique and transformative. The company believes there is significant opportunity to enhance shareholder value by accelerating growth and delivering enhanced financial results with additional investment in these technologies. "Our focus in 2026 is on executing our operational priorities, which include strengthening the balance sheet and improving the overall competitiveness of our portfolio," said Pierre Brondeau, chairman, chief executive officer and president. "In parallel, the Board has authorized the exploration of strategic options to maximize shareholder value and to help ensure our valuable assets and
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.